In this posttrial prespecified secondary analysis of a randomized clinical trial that included 2456 patients with stage II or III colorectal cancer, follow-up testing with computed tomography scans and serum carcinoembryonic antigen screening was performed on 5 vs 2 occasions. The gene discussed is CEACAM5; the disease is colorectal cancer.